Quizartinib is a targeted drug that treats what

Quizatinib is an innovative targeted therapy specifically designed for use in combination with standard cytarabine and anthracycline induction therapy and cytarabine consolidation therapy, and as maintenance monotherapy after consolidation chemotherapy. The drug is primarily intended for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are positive for FLT3 internal tandem duplications (ITD) as confirmed by a U.S. Food and Drug Administration (FDA)-approved test.

FLT3 is a common mutant in acute myeloid leukemia, and its abnormal activation is closely related to the proliferation and survival of leukemia cells. FLT3-ITDmutation is one of the most common molecular abnormalities in AML, and the presence of this mutation often predicts a poor prognosis for patients. Quizartinib specifically inhibits the activity of FLT3 kinase and blocks the cell signaling pathway driven by the FLT3-ITD mutation, thereby effectively inhibiting the proliferation and survival of leukemia cells.

In clinical application, quizartinib has demonstrated significant therapeutic effects. It can not only prolong progression-free survival but also improve overall survival and achieve complete or partial remission in some patients. The emergence of this drug provides a new treatment option for FLT3-ITD-positive AML patients and is expected to improve the prognosis of such patients.

It is worth noting that the use of Quizartinib needs to be done under the guidance of a professional doctor. Doctors will develop a personalized treatment plan based on the patient's specific condition, physical condition and tolerance, and closely monitor the patient's treatment response and possible side effects. In addition, patients need to follow the doctor's recommendations and undergo regular examinations and follow-up during treatment with Quizartinib to ensure the safety and effectiveness of the treatment.

To sum up, quizartinib is a targeted therapy drug for FLT3-ITDpositive AML patients. It blocks the proliferation and survival of leukemia cells by inhibiting the activity of FLT3 kinase, bringing new treatment hope and survival opportunities to such patients.

xa0

Reference: https://go.drugbank.com/drugs/DB12874